Elderly insulin-treated diabetic patients have a high risk of severe hypoglycaemia, yet their hypoglycaemic symptom profile has attracted little research. In this study, the frequency and intensity of symptoms of hypoglycaemia were recorded using a validated questionnaire in 132 insulin-treated diab
Well-being and symptoms in elderly Type 2 diabetes patients with poor metabolic control: Effect of insulin treatment
โ Scribed by Tovi, J ;Engfeldt, P
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 623 KB
- Volume
- 15
- Category
- Article
- ISSN
- 1357-8170
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
The effect of improved metabolic control on wellโbeing and symptoms, with insulin therapy, was investigated in elderly patients with Type 2 diabetes. They had secondary failure on oral therapy, but were without decompensation. A selfadministered wellโbeing questionnaire was used. Patients were randomised to insulin or oral treatment and followed for one year. Initially, diabetic patients (compared with hypertensive controls in the same age group) had significantly lower perception of wellโbeing and more symptoms of tension, depression and pain. After one year, metabolic control improved significantly in the insulintreated group [HbA~1~c fell from 9.3 (1.4)% to 7.3 (1.1)% (p<0.001)] but not in the sulphonylureaโtreated group [HbA~1~c was 9.1 (1.2)% at the start and 9.3 (1.6) % after one year (n.s.d.)]. Improved metabolic control was not associated with improvement in wellโbeing. Insulin therapy, however, reversed symptoms of hyperglycaemia without increasing symptoms of hypoglycaemia and thus seems safe to use in elderly diabetic patients.
๐ SIMILAR VOLUMES
We evaluated the effect of insulin on platelet function, blood viscosity, and filterability in healthy subjects and in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Fifteen diabetic patients were free from cardiovascular complications (group A), while the other 15 patients had both
Background Both HMG-CoA reductase inhibitors and ยฎbric acid derivates are used for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG-CoA reductase inhibitor, and 400 mg bezaยฎbrate, a ยฎbric acid deriva